Background HAS-BLED and CHA2DS2-VASc scores predict bleeding in patients on anticoagulation and thromboembolic (TE) risk in patients with atrial fibrillation, respectively. We hypothesized that these scores would be predictive of bleeding and TE complications following continuous-flow ventricular assist device (CF-VAD) implantation.
Methods and Results Baseline HAS-BLED and CHA2DS2-VASc scores were retrospectively determined for 173 consecutive patients who underwent HeartMate II CF-VAD implantation at a single center from 2005 to 2011. Forty-three patients had bleeding (24.9%) and 22 had TE (12.7%) events over a 290 patient-year follow-up period. The mean ± SD HAS-BLED scores were 2.7 ± 1.0 and 1.9 ± 1.1 (P <.0001) in patients with and without bleeding, respectively. The CHA2DS2-VASc scores were 3.6 ± 1.4 and 2.9 ± 1.5 (P =.03) in patients with and without TE events, respectively. A HAS-BLED score of ≥3 was associated with a significantly higher risk of bleeding events compared with a score of <3 (42% vs 15%, respectively; hazard ratio [HR] 3.40, 95% confidence interval [CI] 1.82-6.32; P <.001). A CHA2DS2-VASc score of ≥3 was associated with a higher risk of TE events compared with a score of <3 (18% vs 4%, respectively; HR 4.02, 95% CI 1.19-13.6; P =.025).
Conclusions Baseline HAS-BLED and CHA2DS2-VASc scores of ≥3 conferred significantly higher risks of bleeding and TE, respectively, following HeartMate II implantation.
Bibliographical noteFunding Information:
Ranjit John has received research grants from Thoratec and HeartWare . Peter Eckman has received honoraria and grant support from Thoratec and HeartWare .
© 2014 Elsevier Inc.
Copyright 2014 Elsevier B.V., All rights reserved.
- Ventricular assist devices
- heart failure
- hemorrhage clotting
- risk factors